Centessa Pharmaceuticals PLC
CNTAHealthcare|Biotechnology|UK
$40.50
+0.00 (+0.00%)
Tangible Book
$3.15
Earnings Power
$1.77
Financials
Financial Snapshot
Market Cap
$6.27B
Enterprise Value
$158.0M
Revenue (TTM)
$15.0M
Net Income (TTM)
$-250.6M
Cash & Equivalents
—
Net Cash/Share
$0.79
Free Cash Flow (TTM)
$-208.8M
Operating CF (TTM)
$-208.8M
Debt/Equity
0.24
Cash Runway & Burn Rate
Cash on Hand
$0.00
Quarterly Burn
$52.2M
Monthly Burn
$17.4M
Est. Runway
—
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $0.00 | $7.2M | $595.1M | $393.6M | $256.5M | $482.2M | $294.6M | $276.6M | |
| Operating Cash Flow | $-5.8M | $-10.6M | $0.00 | $-200.5M | $-160.3M | $-142.1M | $-193.8M | $-208.8M | |
| Free Cash Flow | $-5.8M | $-10.6M | $0.00 | $-201.7M | $-160.5M | $-142.1M | $-194.2M | $-209.0M | |
| Capital Expenditure | $0.00 | $0.00 | $0.00 | $-1.1M | $-169.0K | $-34.0K | $-371.0K | $-245.0K | |
| Financing Cash Flow | $9.0M | $1.4M | $0.00 | $457.0K | $21.1M | $364.8M | $291.5M | $318.9M |
R&D Spending
R&D (TTM)
$198.7M
R&D Intensity
—
R&D Growth YoY
+15.4%
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $6.9M | $0.00 | $15.0M | $0.00 | |
| R&D Expense | $4.3M | $9.3M | $0.00 | $155.1M | $124.4M | $150.2M | $172.2M | $198.7M | |
| R&D % of Revenue | — | — | — | — | 1815.3% | — | 1148.2% | — | |
| SG&A | $790.0K | $1.1M | $0.00 | $55.2M | $53.7M | $50.8M | $50.5M | $58.0M |
Income Statement
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $6.9M | $0.00 | $15.0M | $0.00 | |
| Cost of Goods Sold | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 | $6.9M | $0.00 | $15.0M | $0.00 | |
| R&D | $4.3M | $9.3M | $0.00 | $155.1M | $124.4M | $150.2M | $172.2M | $198.7M | |
| SG&A | $790.0K | $1.1M | $0.00 | $55.2M | $53.7M | $50.8M | $50.5M | $58.0M | |
| Operating Income | $-5.1M | $-10.4M | $0.00 | $-210.3M | $-171.3M | $-201.1M | $-207.7M | $-256.7M | |
| Interest Expense | $-118.0K | $-378.0K | $0.00 | $-7.3M | $-9.9M | $-10.1M | $-11.5M | $-11.3M | |
| Pretax Income | $-5.1M | $-10.7M | $0.00 | $-217.0M | $-176.1M | $-232.9M | $-195.7M | $-249.4M | |
| Net Income | $-5.1M | $-10.7M | $0.00 | $-216.2M | $-151.1M | $-235.8M | $-197.5M | $-250.6M | |
| EPS (Diluted) | -0.07 | -0.15 | 0.00 | -2.31 | -1.57 | -2.06 | -1.46 | -1.79 | |
| EBITDA | $-4.9M | $-10.3M | $0.00 | $-209.5M | $-165.4M | $-221.9M | $-183.3M | $-237.1M | |
| Shares Out. (M) | 70.89 | 70.89 | 85.92 | 93.40 | 96.18 | 114.47 | 135.72 | 153.55 |
Balance Sheet
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $0.00 | $7.2M | $595.1M | $393.6M | $128.0M | $383.2M | $61.3M | $62.4M | |
| Marketable Securities | $0.00 | $0.00 | $0.00 | $0.00 | $128.5M | $99.0M | $233.3M | $214.2M | |
| Total Current Assets | $0.00 | $11.2M | $628.8M | $437.7M | $315.1M | $536.4M | $367.9M | $348.7M | |
| Total Assets | $0.00 | $11.7M | $629.6M | $444.3M | $360.2M | $576.8M | $687.5M | $641.8M | |
| Total Current Liabilities | $0.00 | $8.6M | $24.6M | $38.3M | $39.4M | $58.0M | $42.9M | $36.6M | |
| Long-Term Debt | $0.00 | $0.00 | $75.7M | $69.8M | $75.7M | $108.9M | $110.1M | $110.4M | |
| Total Liabilities | - | $34.1M | $138.1M | $108.1M | $124.0M | $175.3M | $160.6M | $154.4M | |
| Stockholders' Equity | $0.00 | $-22.4M | $491.6M | $336.2M | $236.2M | $401.5M | $526.9M | $487.3M | |
| Retained Earnings | $0.00 | $-22.4M | $-385.7M | $-601.9M | $-752.9M | $-988.7M | $-1.19B | $-1.27B |
Cash Flow Statement
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $-5.8M | $-10.6M | $0.00 | $-200.5M | $-160.3M | $-142.1M | $-193.8M | $-208.8M | |
| Capital Expenditure | $0.00 | $0.00 | $0.00 | $-1.1M | $-169.0K | $-34.0K | $-371.0K | $-245.0K | |
| Free Cash Flow | $-5.8M | $-10.6M | $0.00 | $-201.7M | $-160.5M | $-142.1M | $-194.2M | $-209.0M | |
| Investing Cash Flow | $0.00 | $0.00 | $0.00 | $-931.0K | $-127.0M | $31.3M | $-418.5M | $-153.4M | |
| Financing Cash Flow | $9.0M | $1.4M | $0.00 | $457.0K | $21.1M | $364.8M | $291.5M | $318.9M | |
| Issuance of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $20.8M | $359.6M | $275.4M | $269.2M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Issuance of Debt | $3.8M | $1.4M | $0.00 | $0.00 | $0.00 | $109.3M | $0.00 | $0.00 | |
| Payments of Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $-110.1M | $0.00 | $0.00 | |
| Stock Based Comp. | $236.0K | $336.0K | $0.00 | $25.0M | $29.4M | $33.5M | $31.0M | $33.6M | |
| Net Change in Cash | $3.7M | $-9.3M | $0.00 | $-201.4M | $-265.6M | $255.2M | $-321.3M | $-42.1M |
Dilution Tracker
Shares outstanding grew 78.7% over 5 years — significant dilution
Shares Outstanding
154M
5-Year Share Growth
+78.7%
Stock Issuance (TTM)
$269.2M
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 70.89 | 70.89 | 85.92 | 93.40 | 96.18 | 114.47 | 135.72 | 153.55 | |
| YoY Change % | — | 0.0% | 21.2% | 8.7% | 3.0% | 19.0% | 18.6% | 13.1% | |
| Stock Issuance | $0.00 | $0.00 | $0.00 | $0.00 | $20.8M | $359.6M | $275.4M | $269.2M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $236.0K | $336.0K | $0.00 | $25.0M | $29.4M | $33.5M | $31.0M | $33.6M |
Margins & Profitability
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Margin % | 0.0% | 0.0% | 0.0% | 0.0% | -2499.4% | 0.0% | -1384.6% | - | |
| Net Margin % | 0.0% | 0.0% | 0.0% | 0.0% | -2204.7% | 0.0% | -1316.9% | - | |
| EBITDA Margin % | 0.0% | 0.0% | 0.0% | 0.0% | -2413.9% | 0.0% | -1222.2% | - | |
| FCF Margin % | 0.0% | 0.0% | 0.0% | 0.0% | -2342.2% | 0.0% | -1294.6% | -1392.0% | |
| ROE % | 0.0% | 0.0% | 0.0% | -52.2% | -52.8% | -73.9% | -42.6% | -61.2% | |
| ROA % | - | -91.0% | 0.0% | -40.3% | -37.6% | -50.3% | -31.2% | -44.8% | |
| R&D / Revenue | - | - | - | - | - | - | - | - |
Valuation
P/E (TTM)At Loss
HistoricalAt Loss / At Loss / At Loss
Industry Med.27.51
P/S364.44
Historical98.94 / 220.89 / 364.44
Industry Med.9.49
P/B12.84
Historical3.36 / 5.95 / 13.27
Industry Med.2.93
EV/EBITDA-25.76
Historical-30.37 / -10.63 / -4.93
Industry Med.13.02
EV/Revenue407.24
Historical88.05 / 208.55 / 407.24
Industry Med.8.59
P/FCF—
Historical— / — / —
Industry Med.27.13
Intrinsic Value Models
Tangible Book
$3.15
Net Current Assets
$1.260
Net-Net Working Capital
$0.79
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| PE Ratio | N/A | N/A | N/A | At Loss | At Loss | At Loss | At Loss | At Loss | |
| PS Ratio | - | - | - | - | 112.11 | - | 226.67 | 364.44 | |
| PB Ratio | 0.00 | 0.00 | 2.06 | 0.87 | 3.33 | 5.53 | 7.08 | 12.84 | |
| EV/EBITDA | 0.00 | 0.00 | 0.00 | 0.14 | -3.71 | -7.87 | -19.52 | -25.76 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 89.64 | 0.00 | 238.56 | 407.24 |
Analyst Estimates & Quality
Altman Z-Score
—
Distress
Piotroski F-Score
3
Weak
Beneish M-Score
—
Possible Manipulator
Forward Estimates
| Metric | Current Year | Next Year | 2 Years Out |
|---|---|---|---|
| Revenue | $0.00M | $0.00M | $184.86M |
| Net Income | $-244.56M | $-262.67M | $-237.82M |
| EPS | -1.68 | -1.75 | -1.12 |
| Book Value per Share | 3.18 | 3.16 | 2.93 |
| Operating Cash Flow per Share | 0.00 | 0.00 | 0.00 |
| Operating CF | $0.00M | $0.00M | $0.00M |
Dividends
Revenue Segments
By Business
| Segment | 2025 |
|---|---|
| Single Segment | $15.0M |
By Geography
| Segment | 2025 |
|---|---|
| United Kingdom | $15.0M |